Search results for "Atypical"

showing 10 items of 111 documents

Musculoskeletal Pain in Melancholic and Atypical Depression

2016

Objective. Pain and depressive disorders often present together, but little is known about the prevalence of pain in depression subgroups. The objective of this study was to examine the possible differences in the prevalence of musculoskeletal pain between participants in melancholic and atypical depression subgroups. Design. Cross-sectional study. Setting. Depression nurse case managers where depression patients receive treatment in primary health care. Subjects. Participants included 413 depression patients and 401 controls. Methods. Depressive symptoms were determined with the Beck Depression Inventory (BDI-21), and diagnosis of depression was confirmed with the Mini-International Neurop…

AdultMaleMusculoskeletal painmedicine.medical_specialtyPopulationPhysical Therapy Sports Therapy and RehabilitationLogistic regressionMelancholic depression03 medical and health sciences0302 clinical medicinedepressive disorderInternal medicinePrevalencemedicineHumans030212 general & internal medicinedepression characteristicsPsychiatryeducationAtypical depressionmusculoskeletal painDepression (differential diagnoses)Agededucation.field_of_studybusiness.industryConfoundingBeck Depression Inventoryta3141General MedicineOdds ratioMiddle Agedmedicine.diseaseta3124Cross-Sectional StudiesAnesthesiology and Pain MedicineFemaleNeurology (clinical)business030217 neurology & neurosurgeryPain Medicine
researchProduct

CD99 Immunoreactivity in Atypical Fibroxanthoma

2002

Atypical fibroxanthoma (AFX), a pleomorphic superficial cutaneous tumor of low-grade malignancy, shares many morphologic features with malignant melanoma (MM) and squamous cell carcinoma (SCC). Absence of S-100, keratin, and desmin immunoreactivity is the clue for this diagnosis. In a search for positive markers, we tested 26 cases of AFX with 2 antibodies: O13 (CD99) and protein gene product 9.5 (PGP9.5). We also included 10 cases of poorly differentiated SCC and 10 cases of MM in the study. In AFX, CD99 immunoreactivity was present in 19 cases (73%), whereas focal PGP9.5 immunoreactivity was found in only 9 cases (35%). None of the SCC cases showed CD99 immunostaining. No CD99 immunoreact…

AdultMalePathologymedicine.medical_specialtySkin NeoplasmsCD9912E7 AntigenMalignancyDiagnosis DifferentialAntigens CDBiomarkers TumorCarcinomamedicineHumansMelanomaAgedHistiocytoma Benign Fibrousbusiness.industryMelanomaAtypical fibroxanthomaGeneral MedicineMiddle Agedmedicine.diseaseEpidermoid carcinomaCarcinoma Squamous CellImmunohistochemistryFemaleThiolester HydrolasesbusinessCell Adhesion MoleculesUbiquitin ThiolesteraseImmunostainingAmerican Journal of Clinical Pathology
researchProduct

Soft tissue recurrent ameloblastomas also show some malignant features: a clinicopathological study of a 15-year database

2015

Background To investigate the clinicopathological features of six cases of soft tissue recurrent ameloblastoma and explore the role of increased aggressive biological behavior in the recurrences and treatment of this type of ameloblastomas. Material and Methods In this study, we retrospectively reviewed recurrent ameloblastomas during a 15-year period; six cases were diagnosed as soft tissue recurrent ameloblastoma. The clinical, radiographic, cytological and immunohistochemical records of these six cases were investigated and analyzed. Results All the six soft tissue recurrent ameloblastomas occurred after radical bone resection, and were located in the adjacent soft tissues around the ost…

AdultMalePathologymedicine.medical_specialtySoft Tissue NeoplasmTime FactorsDatabases FactualSoft Tissue NeoplasmsOdontologíaMalignancyAtypical hyperplasiaMalignant transformationAmeloblastomaAtypiaMedicineHumansAmeloblastomaGeneral DentistryPathologicalAgedRetrospective Studiesbusiness.industryResearchSoft tissueMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleOral SurgeryNeoplasm Recurrence Localbusiness
researchProduct

AML transformation in 56 patients with Ph- MPD in two well defined populations.

2009

The Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders (MPD) have an inherent tendency for transformation into acute myelogenous leukaemia (AML). The long-term rate of leukaemic transformation in unselected MPD patients was studied in well-defined MPD populations in Gothenburg, Sweden and the Cote d'Or area, Burgundy, France, respectively. Over a median observation time of 15 yr, 56 subjects (7%) out of a total of 795 patients with Ph- MPD transformed to AML. The yearly incidence of AML transformation was 0.38% in polycythaemia vera (PV), 0.37% in essential thrombocythaemia (ET) and 1.09% in idiopathic myelofibrosis (IMF). The incidence of AML development was signif…

AdultMalePediatricsmedicine.medical_specialtyPolycythaemiaMyeloidIdiopathic myelofibrosisGastroenterologyLeukemia Myeloid Chronic Atypical BCR-ABL Negativehemic and lymphatic diseasesInternal medicineMedicineHumansSurvival analysisAgedAged 80 and overMyeloproliferative Disordersbusiness.industryIncidence (epidemiology)HematologyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisChronic myeloproliferative disordersLeukemiamedicine.anatomical_structureFemalebusinessMale predominanceEuropean journal of haematology
researchProduct

Oxidative stress and antioxidant response in fibroblasts from Werner and Atypical Werner Syndromes

2014

Werner Syndrome (WS, ICD-10 E34.8, ORPHA902) and Atypical Werner Syndrome (AWS, ICD-10 E34.8, ORPHA79474) are very rare inherited syndromes characterized by premature aging. While approximately 90% of WS individuals have any of a range of mutations in theWRN gene, there exists a clinical subgroup in which the mutation occurs in the LMNA/C gene in heterozygosity. Although both syndromes exhibit an age-related pleiotropic phenotype, AWS manifests the onset of the disease during childhood, while major symptoms in WS appear between the ages of 20 and 30. To study the molecular mechanisms of progeroid diseases provides a useful insight into the normal aging process. Main changes found were the d…

AdultMalePremature agingAgingWerner Syndrome HelicaseAdolescentBiologymedicine.disease_causeAntioxidantsCell LineWerner Syndrome HelicaseLMNAProgeriaSuperoxide Dismutase-1antioxidant enzymesmedicineoxidative stressHumansRNA MessengerAtypical Werner syndromeChildeducationCell ProliferationWerner syndromeeducation.field_of_studyProgeriaAtypical Werner SyndromeRecQ Helicasespremature agingSuperoxide DismutaseAging PrematurethioredoxinglutaredoxinCell BiologyFibroblastsLamin Type Amedicine.diseaseGlutathioneMolecular biologyExodeoxyribonucleasesCase-Control StudiesMutationDNA damageFemaleWerner SyndromeThioredoxinOxidative stressResearch PaperAging
researchProduct

Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and cha…

1995

Preclinical data indicated that seroquel (ICI 204 636), a dibenzothiazepine with 5-HT2 and D2-like receptor antagonistic properties, might be an effective antipsychotic agent, causing fewer extrapyramidal side effects than typical neuroleptics. In the present study, 12 patients suffering from schizophrenia or schizophreniform disorder with predominantly positive symptomatology were treated in an open clinical trial for 4 weeks with seroquel at a maximum dosage of 750 mg/day. The drug was generally well tolerated, and virtually no adverse extrapyramidal side effects such as acute dystonia, parkinsonism or akathisia were observed. Total scores for BPRS (item score 0–6; baseline: 42.0±2.3; mea…

AdultMalePsychosismedicine.medical_specialtyDibenzothiazepinesTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticThyrotropinAkathisiaGastroenterologyQuetiapine FumarateAntipsychotic AgentInternal medicinemedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesParkinsonismElectroencephalographyMiddle Agedmedicine.diseaseProlactinTreatment OutcomeSchizophreniaAnesthesiaSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologyAntipsychotic AgentsPsychopharmacology
researchProduct

Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Posit…

1997

MDL 100,907 is a potent and selective antagonist of 5-HT2A serotonin receptors. Animals studies suggest that MDL 100,907 may behave as an atypical antipsychotic drug. Positron emission tomograph (PET) using [11C]NMSP as the radiotracer was used to define the time course of 5-HT2 receptor occupancy in the human frontal cerebral cortex after a single oral dose of MDL 100,907 (10 or 20 mg) in nine healthy subjects. After the baseline scan each subject was studied three times post dosing at various time points. 5-HT2 occupancies were in the range of 70 and 90% after each dose. While the occupancy remains in this range over 24 hours after 20 mg MDL 100,907, it decreases by about 20% at 24 hours …

AdultMaleTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyPiperidinesOral administrationmedicineHumansReceptor Serotonin 5-HT2ACarbon RadioisotopesPositron emissionDosing5-HT receptorPharmacologymedicine.diagnostic_testbusiness.industry5-HT2 receptorBrainHuman brainFluorobenzenesPsychiatry and Mental healthmedicine.anatomical_structureSpiperonePositron emission tomographyReceptors SerotoninFemaleSerotonin AntagonistsbusinessAntipsychotic AgentsTomography Emission-ComputedNeuropsychopharmacology
researchProduct

Dose-Related Effects of Amisulpride on Five Dimensions of Psychopathology in Patients With Acute Exacerbation of Schizophrenia

2002

The present analysis investigated symptom-specific dose-response relationships of the atypical antipsychotic amisulpride (AMI) in schizophrenic patients. The effects of different AMI doses on five different symptom dimensions of the Brief Psychiatric Rating Scale (BPRS) were analyzed. Results on global efficacy and safety parameters have been previously published. Four AMI doses (100 mg/day [AMI100], 400 mg/day [AMI400], 800 mg/day [AMI800], 1200 mg/day) were compared with 16 mg haloperidol (HAL16) in a multicenter, double-blind, randomized, parallel-group, 4-week trial. A total of 319 patients with acute exacerbation of schizophrenia (DSM-III-R) were included. AMI100 was compared with the …

AdultMalemedicine.medical_specialtyAdolescentExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmisulpridePsychiatryAntipsychoticPsychiatric Status Rating ScalesDose-Response Relationship DrugDopamine antagonistMiddle AgedPsychiatry and Mental healthTreatment OutcomeSchizophreniaHaloperidolAnxietyFemaleSchizophrenic PsychologyAmisulprideSulpiridemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Clinical Predictors of Response to Magnetic Seizure Therapy in Depression

2019

Objectives Magnetic seizure therapy (MST) is a novel convulsive brain stimulation method in clinical testing, which is used as an alternative for electroconvulsive therapy in patients with treatment-resistant depression (TRD). Preliminary studies have suggested that MST leads to fewer cognitive adverse effects than electroconvulsive therapy but has similar efficacy. However, the clinical predictors of response to MST have not been evaluated yet. This study aimed to investigate whether these predictors can be identified in patients with TRD. Methods Thirty-eight patients with TRD were included. As clinical predictors for treatment response, we used the diagnosis, sex, age, family history, an…

AdultMalemedicine.medical_specialtyAnhedoniaMagnetic Field Therapymedicine.medical_treatmentNeuroscience (miscellaneous)Depressive Disorder Treatment-Resistant03 medical and health sciences0302 clinical medicineElectroconvulsive therapyPredictive Value of TestsSeizuresInternal medicinemedicineHumansFamily historyAtypical depressionDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressionbusiness.industryHamilton Rating Scale for DepressionMiddle Agedmedicine.disease030227 psychiatryPsychiatry and Mental healthTreatment OutcomeMagnetic seizure therapyBrain stimulationAnxietyFemalemedicine.symptombusinesshuman activities030217 neurology & neurosurgeryThe Journal of ECT
researchProduct

The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study…

2010

Abstract Background Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics; nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with long-term antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional versus novel antipsychotic drugs) on cognitive performance over time. Methods In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of schizophrenia patients taking either conventional (n = 13) or novel a…

AdultMalemedicine.medical_specialtyCognition disorderslcsh:RC435-571Teràpia cognitivamedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticPilot ProjectsComorbidityCognitive therapyNeuropsychological TestsTrastorns de la cogniciólcsh:PsychiatryResearch articlemedicineHumansVerbal fluency testLongitudinal StudiesAntipsychotic drugsEffects of sleep deprivation on cognitive performancePsychiatryAntipsychoticRetrospective StudiesPsychiatric Status Rating ScalesCognitionExecutive functionsmedicine.diseasePsychiatry and Mental healthTreatment OutcomeSchizophreniaSchizophreniaFemaleSchizophrenic PsychologyAntipsicòticsEsquizofrèniaVerbal memoryCognition DisordersPsychologyAntipsychotic AgentsClinical psychologyBMC Psychiatry
researchProduct